Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 901–1,000 of 1,001
Structure and Thermodynamics of Drug-RNA Aptamer Interactions
Costa, J. B. D., & Dieckmann, T. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557511313040001 · Cited by 6
“The NF-b factor is involved in activating genes and has been the target of therapeutic inhibition of cancer cells [62].”
BackgroundCompanion Animals as Models for Inhibition of STAT3 and STAT5
Kieslinger, M., Swoboda, A., Kramer, N., Pratscher, B., Wolfesberger, B., & Burgener, I. A. (2019) · Cancers · doi:10.3390/cancers11122035 · Cited by 7
“These findings lead to the concept of STAT3 and STAT5 constituting a “signaling bottleneck” situation for tumor cells, making them attractive targets for inhibition [98].”
BackgroundWang, N., Wu, D., Qian, L., Yan, Y., Chen, X., Zhao, Z., Yan, H., Zhang, X., Xu, M., Deng, W., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16156 · Cited by 6
Activity in MCF-7 Estrogen-sensitive Breast Cancer Cells of Capsicodendrin fromCinnamosma fragrans
Acuña, U. M., Ezzone, N. P. M., Harinantenaina, L., & de Blanco, E. J. C. (2021) · Anticancer Research · doi:10.21873/anticanres.15412 · Cited by 6
Liu, Y., Du, J., Choi, J., Chen, K., Hou, S., Yan, M., Lin, W., Chen, K. S., Ro, T., Lipshutz, G. S., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201507546 · Cited by 6
Protein‐Controlled Actuation of Dynamic Nucleic Acid Networks by Using Synthetic DNA Translators**
Bertucci, A., Porchetta, A., Grosso, E. D., Patiño, T., Idili, A., & Ricci, F. (2020) · Angewandte Chemie · doi:10.1002/ange.202008553 · Cited by 6
Rac and Nuclear Translocation of Signal Transducers and Activators of Transcription Factors
Kawashima, T., & Kitamura, T. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)00413-2 · Cited by 8
Analysis of differentially expressed genes in malignant biliary strictures
Qi, D., Wu, B., Tao, S. L., Zhou, J., Qian, H. X., & Wang, D. (2014) · Genetics and Molecular Research · doi:10.4238/2014.april.8.10 · Cited by 7
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6
Design, Synthesis and Evaluation of WD-repeat containing protein 5 (WDR5) degradersPreprint
Dölle, A., Adhikari, B., Krämer, A., Weckesser, J., Berner, N., Berger, L. M., Diebold, M., Szewczyk, M. M., Baršytė-Lovejoy, D., Arrowsmith, C. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.12.439490 · Cited by 6
Harada, T., Perez, M. W., Kalfon, J., Braes, F. D., Batley, R., Eagle, K., Nabet, B., Leifer, B. S., Kruell, J. A., Paralkar, V. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.07.536032 · Cited by 7
Chen, T.-Q., Huang, H., Zhu, S.-X., Chen, X.-T., Pu, K., Wang, D., An, Y., Lian, J.-Y., Sun, Y., Chen, Y., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00488-5 · Cited by 5
“Thus, these types of fusion proteins are generally deemed undruggable [1, 45–47], and the therapeutic options remain largely under developed.”
BackgroundHuang, C., Chang, C., Chen, C.-W., Ho, S.-Y., Chang, H., & Chu, Y.-W. (2018) · Genes · doi:10.3390/genes9020091 · Cited by 6
Targeting Proteins in Nucleus through Dual-Regulatory Pathways Acting in Cytoplasm
Wu, X., Hu, J., Chen, L., Chen, Z., Wang, T., Wu, F., Dai, J., Xia, F., & Lou, X. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c01815 · Cited by 5
CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma
Cai, Y., Hirata, A., Nakayama, S., VanderLaan, P. A., Levantini, E., Yamamoto, M., Hirai, H., Wong, K., Costa, D. B., Watanabe, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120647 · Cited by 5
“These oncogenic events lead to changes in transcription patterns, resulting in a block in differentiation, suppression of apoptosis, and uncontrolled proliferation [6].”
BackgroundAntioxidant and Anti-inflammatory Action of Thymoquinone
Khan, A. (2018) · Springer eBooks · doi:10.1007/978-981-10-8800-1_4 · Cited by 9
Decreased levels of both Stat1 and Stat3 in T lymphocytes from mice bearing mammary tumors.
Handel-Fernandez, M. E., Ilkovitch, D., Iragavarapu‐Charyulu, V., Herbert, L. M., & Lopez, D. M. (2009) · PubMed · Cited by 6
Mining Massive Amounts of Genomic Data: A Semiparametric Topic Modeling Approach
Fang, E. X., Li, M., Jordan, M. I., & Liu, H. (2016) · Journal of the American Statistical Association · doi:10.1080/01621459.2016.1256812 · Cited by 6
“Transcription factors (TFs) and cofactors represent major regulators of gene expression, the disturbance of which contributes to the pathogenesis of a plethora of human diseases, including cancer (Darnell 2002; Arrowsmith et al. 2012).”
BackgroundActivating p53 Y220C with a Mutant-Specific Small MoleculePreprint
Zhu, X., Byun, W. S., Pieńkowska, D. E., Nguyen, K. T., Gerhartz, J., Geng, Q., Qiu, T., Zhong, J., Jiang, Z., Wang, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.23.619961 · Cited by 5
“Overactivity of oncogenic transcription factors and loss of tumor suppressor transcription factors both enable cancer cells to escape normal control of cell proliferation 36 .”
BackgroundMultimodal foundation model predicts zero-shot functional perturbations and cell fate dynamicsPreprint
Yang, Z., Fan, X., Lan, M., Tang, X., Zheng, Z., Liu, B., You, Y., Tian, L., Church, G. M., Liu, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.19.629561 · Cited by 5
Zhu, J., Bao, L., Xu, S., & Ji, X. (2025) · Science Advances · doi:10.1126/sciadv.adz2345 · Cited by 5
Ray, U., Singh, A., Samanta, D., & Dhar, R. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00640-9 · Cited by 6
“GiventheimportanceofTFsincancertransformationandphenotypic plasticity, they could be good targets for anticancer therapy 31 – 33 and recent research has uncovered many potential ways to target them 34,35 .”
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 7
Wang, Z., He, X., Zhang, X., Spiegel, J., Flynn, S. M., & Balasubramanian, S. (2026) · Nature Chemistry · doi:10.1038/s41557-026-02111-y · Cited by 8
“A notable example is the SWI/SNF chromatin remodeller complex, a multisubunit assembly that regulates gene expression by repositioning nucleosomes to facilitate transcription, which plays critical regulatory roles in disease states, including cancers 3,20 .”
Lin, T.-C., Chung, P.-J., Shen, C.-A., Nguyen, T. M. H., Lin, Y., Lin, S., Hsiao, S., & Chiu, W. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151332 · Cited by 5
FOXJ3, a novel tumor suppressor in neuroblastoma
Challagundla, K. B., Pathania, A. S., Chava, H., Kantem, N. M., Dronadula, V. M., Coulter, D. W., & Clarke, M. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200914 · Cited by 4
Shimada, H., Sementa, A. R., Pawel, B., & Ikegaki, N. (2019) · Springer eBooks · doi:10.1007/978-3-030-18396-7_4 · Cited by 6
The New Model of Carcinogenesis: The Cancer Stem Cell Hypothesis
Loaiza, B., Rojas, E., & Valverde, M. (2012) · InTech eBooks · doi:10.5772/38324 · Cited by 8
Tying up a transcription factor
Chen, A., & Koehler, A. N. (2015) · Science · doi:10.1126/science.aaa6119 · Cited by 4
Nagumo, T., Ito, D., Tsukamoto, H., Yasuda, A., & Shintani, S. (2011) · Asian Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ajoms.2011.06.007 · Cited by 4
Su, N., Dai, D., Deng, C., Qian, M., & Deng, M. (2014) · IET Systems Biology · doi:10.1049/iet-syb.2013.0029 · Cited by 4
“In addition, we also select ten TFs that related with cancer [5] as E2F1, NR3C1, JUN, JUNB, JUND, MAX, MYC, TP53, SPI1 and STAT1.”
BackgroundSTAT3 Nuclear Egress Requires Exportin 7 via Engaging Lysine Acetylation
Yu, A. H. H. (2014) · MOJ Cell Science & Report · doi:10.15406/mojcsr.2014.01.00004 · Cited by 4
Characterization of transcription factor response kinetics in parallel
Bilgin, B., Nath, A., Chan, C., & Walton, S. P. (2016) · BMC Biotechnology · doi:10.1186/s12896-016-0293-6 · Cited by 4
Romanchikova, N., Strods, A., Strazdina, J., Štrumfs, B., & Trapencieris, P. (2016) · Anticancer Research · doi:10.21873/anticanres.11204 · Cited by 4
Facile Synthesis of 2-Phenylquinoline-4-carboxamide Derivatives with Variant Structural Features
Okawara, T., Islam, R., Hossain, M. I., Okamoto, Y., Nagamatsu, T., & Anraku, K. (2014) · Heterocycles · doi:10.3987/com-14-12939 · Cited by 4
Jasim, S. A., Almajidi, Y. Q., Al‐Rashidi, R. R., Hjazi, A. M., Ahmad, I. S., Alawadi, A. H., Alwaily, E. R., Alsaab, H. O., Haslany, A., & Hameed, M. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3971 · Cited by 5
Hou, P., Fan, Q., Zhang, Q., Liu, J., & Wu, Q. (2024) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13868 · Cited by 4
“7,8 As a class of multidomain proteins with specific DNA-binding and regulatory domains, transcription factors typically function through binding to short, nucleotide-specific DNA sequences located in the promoter regions of target genes.”
BackgroundJak/STAT Signaling in the Pathogenesis and Treatment of Multiple Myeloma
Nelson, E. A., Walker, S. R., & Frank, D. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_7 · Cited by 4
de Oliveira, M. L. G., Assenço, R. A. G., Silva, G. D. D. F., Lopes, J. C. D., Silva, F. C., Lanna, M. C. D. S., de Magalhães, J. C., Duarte, L. P., & Filho, S. A. V. (2014) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 8
DNA Wires and Electron Transport Through DNA
Yamana, K., Erbe, A., Barton, J. K., Furst, A. L., Grodick, M. A., Choi, J., & Majima, T. (2015) · Wiley eBooks · doi:10.1002/9781118696880.ch2 · Cited by 4
Moon, K. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-2235-5 · Cited by 4
Fabrication of duplex DNA microarrays incorporating methyl-5-cytosine
Warren, C. L., Zhao, J., Glass, K., Rishi, V., Ansari, A. Z., & Vinson, C. (2011) · Lab on a Chip · doi:10.1039/c1lc20698b · Cited by 4
Polyamide als artifizielle Transkriptionsfaktoren: neue Hilfsmittel der molekularen Medizin?
Schmitz, K., & Schepers, U. (2004) · Angewandte Chemie · doi:10.1002/ange.200301745 · Cited by 5
Oncogenic Transcription Factors: Target Genes
Paccez, J. D., & Zerbini, L. F. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0006049.pub2 · Cited by 4
Identification of novel small molecule inhibitors of ETS transcription factors
Abdalla, S., Forghany, Z., Ma, J., Hollander, J. G., Nachane, R., Szuhai, K., Hogendoorn, P. C. W., ten Dijke, P., Shah, D., & Baker, D. A. (2025) · FEBS Letters · doi:10.1002/1873-3468.70040 · Cited by 3
“In this context, Darnell [16] was correct to argue that there are a limited number of overactivated transcription factors in cancer, which could be suitable candidates for the development of anticancer drugs.”
El-Desouky, S. I., Nafie, M. S., Haffez, H., Moustafa, M. A. A., & Ali, A. R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108821 · Cited by 5
Lazarte, J. M. S., Aare, M., Padakanti, S. C., Bagde, A., Nathani, A., Meeks, Z., Sun, L. J., Li, Y., & Singh, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101318 · Cited by 3
Protein–DNA interactions in disease and drug discovery
Mishra, R., & Ahmad, S. (2025) · Chemical Communications · doi:10.1039/d5cc06239j · Cited by 5
Chen, Y., Xu, H., Chen, L., Zhang, M., Yang, D., Tong, M., Shi, X., Liu, Z., & Chen, G. (2022) · New Journal of Chemistry · doi:10.1039/d2nj05206g · Cited by 3
BIT: Bayesian Identification of Transcriptional regulators from epigenomics-based query region sets
Lu, Z., Xu, L., & Wang, X. (2025) · Nature Communications · doi:10.1038/s41467-025-60269-4 · Cited by 2
“Thus, gaining insights into the identity and function of TRs that regulate speci fi c biological processes is essential in a broad range of biological and medical research, particularly in fi nding biomarkers and ther-apeutictargets 14 – 16 .”
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.734 · Cited by 3
Zhang, Y., Liu, F., Nie, J., Jiang, F., Zhou, C., Yang, J., Fan, J., & Li, J. (2014) · The Analyst · doi:10.1039/c4an00096j · Cited by 3
Shin, D., Jung, S. N., Yun, J., Lee, C. W., Han, D. C., Kim, B., Min, Y. K., Kang, N. S., & Kwon, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.02.017 · Cited by 3
Yenerall, P. M., & Kittler, R. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1199 · Cited by 3
“challenging despite recent progress (1, 2).”
Bhayye, S. S., Brahmachari, G., Nayek, N., Roy, S., & Roy, K. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1606735 · Cited by 3
“…for cancer therapeutics are DNA and associated factors (Helleday, Petermann, Lundin, Hodgson, & Sharma, 2008; Hurley, 2002), transcription factors (Darnell, 2002), integrins (Tucker & Tucker, 2006), kinases (Gschwind, Fischer, & Ullrich, 2004; Sawyers, 2004), targets involving cellular signalling…”
DriverMP enables improved identification of cancer driver genes
Liu, Y., Han, J., Kong, T., Xiao, N., Mei, Q., & Liu, J. (2022) · GigaScience · doi:10.1093/gigascience/giad106 · Cited by 4
Ladwig, A., Gupta, S. K., Ehlers, P., Sekora, A., Alammar, M., Koczan, D., Wolkenhauer, O., Junghanß, C., Langer, P., & Escobar, H. M. (2023) · Molecules · doi:10.3390/molecules28248120 · Cited by 4
Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment
Lee, D. H., Yoo, J. K., Um, K. H., Ha, W., Lee, S. M., Park, J., Kye, M. J., Suh, J., & Choi, J. W. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03088-7 · Cited by 4
“Targeting STAT3 has proved to be arduous due to unforeseen downstream ramifications and its non-enzymatic properties [18, 19].”
Yue, P., Chen, Y., Ogese, M. O., Sun, S., Zhang, X., Esan, T., Buolamwini, J. K., & Turkson, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400351 · Cited by 3
The Link of Interferon Regulatory Factors 4 and 7 on the Patient’s Survival in Lung Adenocarcinoma
Kara, A., Aydin, A., Morva, A., Ceker, D., Küçüker, S., & Karadağ, A. (2018) · International Conference on Cancer Care Informatics (CCI) · doi:10.1109/cancercare.2018.8618159 · Cited by 3
“A number of transcription factors involved in oncogenic signalling have been proposed as targets for the development of anticancer therapeutics (5).”
BackgroundQian, G., Xu, J., Shen, X., Wang, Y., Zhao, D., Qin, X., You, H., & Liu, Q. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1758088 · Cited by 3
Farahat, A. A., Iwamoto, S., Roche, M. J., & Boykin, D. W. (2021) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4353 · Cited by 3
Secondary structures, dynamics, and DNA binding of the homeodomain of human SIX1
Li, Y., Ng, E. Y., Loh, Y. R., Gea, C. Y., Huang, Q., Li, Q., & Kang, C. (2021) · Journal of Peptide Science · doi:10.1002/psc.3376 · Cited by 3
“Both the SD-HD (1-189) construct and HD construct (consisting of residues G124-K185) of human SIX1 were able to be purified from E.”
BackgroundMethodThe surprises of mammalian molecular cell biology
Darnell, J. E., Jr. (2002) · Nature Medicine · doi:10.1038/nm773 · Cited by 3
Targeting JAK-STAT signal transduction pathways in human carcinomas
(2013) · International Journal of Biosciences (IJB) · doi:10.12692/ijb/3.8.241-250 · Cited by 3
Discovery of Novel Transcription Factor Inhibitors Using a Pyrazole-based Small Molecule Library
Ha, H. (2008) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2008.29.2.323 · Cited by 3
Limits And Prospects Of Methods For The Analysis Of DNA-Protein Interaction
(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608054923113010009 · Cited by 3
Apoptotic Effect of Wortmannolone on Cancer Cells through Potent ROS Induction.
Acuña, U. M., Fatima, N., Ahmed, S., Chang, L. C., & de Blanco, E. J. C. (2013) · PubMed · Cited by 3
Analysis of Regulatory and Interaction Networks from Clusters of Co-expressed Genes
Yang, E., Misra, A., Maguire, T. J., & Androulakis, I. P. (2009) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812771667_0003 · Cited by 3
Transcription Factors in the Central Nervous System
Schochet, T. L., Lovatt, D., & Eberwine, J. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00027-4 · Cited by 4
Tomar, N., Mishra, A., Mrinal, N., & Jayaram, B. (2016) · Database · doi:10.1093/database/baw116 · Cited by 3
“Such molecules are designed to regulate biological processes such as transcription to control expression of aberrant gene in a diseased state like cancer (36, 37).”
BackgroundLathbridge, A., Michalowska, A. S., & Mason, J. M. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00631 · Cited by 3
Cancer drug target identification and node-level analysis of the network of MAPK pathways
Aksam, V. K. M., Chandrasekaran, V. M., & Pandurangan, S. (2018) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-018-0165-1 · Cited by 3
Hubé, F. (2006) · Frontiers in bioscience · doi:10.2741/1905 · Cited by 3
Development of novel therapeutic approaches for the reduction of apolipoprotein B expression
Mclaughlin, C. (2014) · Figshare · doi:10.13140/rg.2.1.3104.7840 · Cited by 5
Robust causal structure learning with some hidden variablesPreprint
Frot, B., Nandy, P., & Maathuis, M. H. (2017) · arXiv (Cornell University) · doi:10.3929/ethz-b-000346513 · Cited by 3
Sadalge, D., Clasman, J. R., Topal, S., Musser, D., Von der Porten, L., Wu, S., Schultz, S. E., Austin, W., Huang, D., Gao, Y.-D., et al. (2025) · doi:10.1101/2025.08.01.667454 · Cited by 2
Zhou, B., Yang, J., Zhang, B., Wang, W., Li, J., & Zhang, Y. (2025) · ChemBioChem · doi:10.1002/cbic.202500545 · Cited by 2
Oxidative stress and cancer metabolism: From pathogenesis to therapeutic opportunities
Agnihotri, T. G., Gomte, S. S., Rout, B., Peddinti, V., Maharana, S. K., Yallappa, D., & Jain, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33459-7.00006-5 · Cited by 4
Barhela, K., Chaudhary, A. A., Mishra, R., Nupur, N., Magani, S. K. J., Rudayni, H. A., Kumar, S., & Kumar, B. (2025) · ACS Omega · doi:10.1021/acsomega.5c09485 · Cited by 3
“47 In this review, there are several transcriptional factors studied that are critically associated with cancer stem cell phenotypes of the tumor cells, mediating drug resistance and cancer recurrence.”
Promoter‐Targeting RNA Technologies: An Epigenetic Strategy for Gene Activation and Gene Silencing
Hegde, R., Ajees, M. A., Damodar, K. S. H., Poojary, E., Hegde, S., & Kabekkodu, S. P. (2026) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.70043 · Cited by 2
“This method may be particularly beneficial for targeting transcription factors involved in multiple pathways, which are frequently overexpressed in cancer and neurological disease but are challenging to treat with conventional small-molecule drugs (Darnell Jr. 2002; Hu et al. 2020).”
Hasdemir, H. S., Li, Y., Kelich, P., Wen, P., & Tajkhorshid, E. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5054-7_1 · Cited by 5
Chen, H., Fu, R., & Wu, Z. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01877-8 · Cited by 3
“TFs drive a wide spectrum of malignant capabilities, including self-renewal, dedifferentiation, metabolic reprogramming, epithelial-mesenchymal transition (EMT), angiogenesis, and resistance to cytotoxic and targeted therapies [7].”
Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer
Ljungman, D., & Cusack, J. C. (2007) · Humana Press eBooks · doi:10.1385/1-59259-893-5:209 · Cited by 2
Regulation of non-coding RNAs by phytochemicals for cancer therapy
Verma, S. S., Rai, V., Shukla, K. K., & Gupta, S. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816843-1.00022-9 · Cited by 2
Role of Activator Protein-1 Transcription Factor in Oral Cancer
Srushti, S. C., Kumar, M. N., Hegde, S., Biradar, S., Shreedevi, S. J., Prashanth, S., & Babu, R. L. (2022) · Current Cancer Therapy Reviews · doi:10.2174/1573394719666221115121128 · Cited by 2
Tsuruta, A., Kanetani, D., Shiiba, Y., Inoki, T., Yoshida, Y., Matsunaga, N., Koyanagi, S., & Ohdo, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115708 · Cited by 2
Aloqbi, A. A. (2024) · Advancements in Life Sciences · doi:10.62940/als.v11i2.2975 · Cited by 2
SOXs: Master architects of development and versatile emulators of oncogenesis
Saloni, Sachan, M., Rahul, Verma, R. S., & Patel, G. K. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189295 · Cited by 2
Liu, L., Ma, C., Ji, J., Gao, R., & Li, D. (2025) · Oncology Letters · doi:10.3892/ol.2025.15006 · Cited by 2
“IL‑6, discovered in 1976 (26), is a glycosylated protein composed of 184 amino acids (27) and a pleiotropic cytokine, which not only participates in immune response, but also in the basic processes such as inflammation, hematopoi‑ etic function, bone metabolism and embryonic development.”
Chemical Control of Genes: Synthetic Genome Readers and Gene Regulators
Ansari, A. Z., Mohammed, A., Achari, A., Danda, A., Philips, S. J., Deane, C. D., & Kandikonda, S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00112 · Cited by 2
High Expression of PDIA4 Contributes to Poor Prognosis in Glioma
Liu, Y., He, H., Zou, Y., Feng, J., Liu, H., Gao, P., Lu, W., Zhao, Y., & Ma, H. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.70042 · Cited by 2
“Cancer cells require elevated protein expression compared to normal cells, achieved through enhanced transcriptional and translational processes [29], including the upregulation of protein disulfide isomerases (PDIs) to support enhanced protein folding required for elevated protein synthesis in…”
A higher proportion of craniosynostosis genes are cancer driver genes
Misra, S., Shih, A., Yan, X., & Li, W. (2025) · Human Gene · doi:10.1016/j.humgen.2025.201378 · Cited by 2
A system biology approach for understanding the miRNA regulatory network in colon rectal cancer
Pradhan, M. P., Nagulapalli, K., Ledford, L., Pandit, Y., & Palakal, M. J. (2014) · International Journal of Data Mining and Bioinformatics · doi:10.1504/ijdmb.2015.066332 · Cited by 2
“As transcription factors, which are considered, like miRNAs, to be powerful gene regulators, affect most of the genes in the genome, they have been discovered to be associated with a wide range of cancers (Darnell, 2002).”
BackgroundFu, S., Pan, X., & Fang, W. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2300 · Cited by 2
“Furthermore, ETV4 was demonstrated to be a useful marker in study on prostate cancer (48), and JUND and its target gene PLAU were shown to have an important role in gene expression in cancer cells (49).”
Stat3 Oncogenic Signaling in Glioblastoma Multiforme
Haque, S. J., & Sharma, P. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-553-8_37 · Cited by 2
Omega-3 Fatty Acids in Cancer Prevention and Control: A Membrane Perspective
Turk, H. F., Monk, J. M., Hou, T. Y., & Chapkin, R. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6819-6_12 · Cited by 2
Microfluidic Chromatin Immunoprecipitation for Analysis of Epigenomic Regulations
Zhu, Y., & Lu, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-30019-1_16 · Cited by 2
Anticancer Mechanisms of Actin Depolymerization Agent Pectenotoxin-2
Kim, G., & Choi, Y. H. (2012) · CRC Press eBooks · doi:10.1201/b13868-29 · Cited by 2
NOTCH1 mutation in type II Hodgkin transformation of chronic lymphocytic leukemia
McGovern, B., Quinn, F., Andrews, C., Jeffers, M. D., Bacon, C. L., Bird, B., Crotty, G. M., Vandenberghe, E., & Flavin, R. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1211278 · Cited by 2
“[3] The NOTCH1 gene encodes a class I transmembrane protein functioning as a ligand-activated transcription factor.[4] In mature B-lymphocytes, NOTCH1 signaling promotes terminal differentiation to antibody-secreting cells.”
Background
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.